LITS — Lite Strategy, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1262104 ·
Last close
$1.36
Market Cap
$46.27M
52W High
$2.97
52W Low
$0.69
ADV30
681,843
Next earnings
2026-09-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -2,765,000 | -23,694,000 | 57,789,000 | 7,544,000 | 952,000 |
| Dec 2025 | 0 | — | -3,351,000 | -30,799,000 | 82,937,000 | 8,758,000 | 1,087,000 |
| Sep 2025 | 0 | — | -3,108,000 | -3,639,000 | 113,337,000 | 10,113,000 | 1,068,000 |
| Jun 2025 | 0 | — | -2,878,000 | -2,688,000 | 18,285,000 | 18,011,000 | 1,354,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,418,000
Investing CF
$-97,333,000
Financing CF
$94,823,000
CapEx
—
Dividends Paid
$0
Buybacks
$-1,792,000
EPS Diluted TTM
$-1.99
As of
2026-09-06
Balance + Analyst (yfinance extras)
Retained Earnings
$-462,296,000
Inventory
—
Receivables
—
ST Investments
$2,084,000
EBIT TTM
$-12,102,000
Pretax Income TTM
$-60,820,000
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 0 | -17,455,000 | -15,945,000 | 18,285,000 | 1,354,000 | 16,931,000 | -20,844,000 |
| Jun 2024 | 65,297,000 | 25,441,000 | 17,778,000 | 41,375,000 | 8,355,000 | 33,020,000 | -50,473,000 |
| Jun 2023 | 48,816,000 | -36,764,000 | -31,838,000 | 120,809,000 | 96,185,000 | 24,624,000 | -52,484,000 |
| Jun 2022 | 40,697,000 | -75,484,000 | -54,454,000 | 177,840,000 | 125,427,000 | 52,413,000 | -48,746,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DWTX | Dogwood Therapeutics, Inc. | $46.23M | $1.36 | — |
| BYSI | BeyondSpring Inc. | $46.05M | $1.12 | — |
| SCYX | SCYNEXIS INC | $45.97M | $4.62 | — |
| HOWL | Werewolf Therapeutics, Inc. | $45.20M | $0.93 | — |
| GRCE | Grace Therapeutics, Inc. | $44.60M | $2.12 | — |
News headlines (Yahoo Finance, 1h cache)
Exclusive: Lite Strategy leads $1m investment in Litecoin Layer 2 platform LitVM
2026-06-18 11:45 · Yahoo
Is Lite Strategy (NASDAQ:LITS) In A Good Position To Invest In Growth?
2026-04-25 12:42 · Yahoo
Can LitVM Bring Smart Contracts to Litecoin Without Changing Its Identity?
2026-06-23 08:15 · Yahoo
Sellas’ Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global – Analyst Sees About 200% Upside Potential
2026-08-12 16:07 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.